Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 623

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 623
---
 the post-transaction company.

Third Amendment to the C&E Agreement

On August 29, 2023, the C&E Agreements were further amended to revise the definition of an Approved deSPAC Transaction to remove the minimum cash balance condition of $30 million.

Termination of C&E Agreement with Novakera, LLC

On August 8, 2024, Longevity terminated the C&E Agreement with Novokera LLC pursuant to Section 10.1(b) of the C&E Agreement due to multiple conditions not being satisfied or waived to close a business combination by October 25, 2023. Cerevast and Aegeria Soft Tissue, LLC remained parties to the C&E Agreements and remained Target Companies.

Fourth Amendment to the C&E Agreement

On August 8, 2024, Longevity entered into amendments to the C&E Agreements with the remaining Target Companies and each of the Target Companies respective shareholders and unitholders pursuant to which certain provisions of the C&E Agreements were amended to, among other things: modify the aggregate valuation assigned to Longevity reflecting a business combination and modify the allocation of the transaction consideration among the Target Companies and FutureTech II Acquisition Corp. (“FutureTech II”), see Note 9.

| F-101 |

<div align='center'>CEREVAST MEDICAL, INC.

NOTES TO FINANCIAL STATEMENTS (UNAUDITED)</div>

Note 9 – Merger Agreements

Denali Capital Acquisition Corp. Merger Agreement

On January 25, 2023, pursuant to the objectives of the Acquisition Transactions contemplated by the C&E Agreement and the agreements with the other Target Companies, Longevity entered into an Agreement and Plan of Merger (the “Denali Merger Agreement”) with Denali Capital Acquisition Corp. (“Denali”), a blank-check special purpose acquisition company, Denali SPAC Holdco, Inc. (“New Pubco”), Denali SPAC Merger Sub, Inc., Longevity Merger Sub, Inc., and Bradford A. Zakes (Cerevast CEO and Longevity CEO), in the capacity as seller representative.

On June 27, 2024, Denali and Longevity mutually agreed to terminate the Denali Merger Agreement.

FutureTech II Acquisition Corp. Merger Agreement

On September 16, 2024, pursuant to the objectives of the Acquisition Transactions contemplated by the C&E Agreement and the agreements with the Target Companies, Longevity entered into an Agreement and Plan of Mer